| MeSH term | MeSH ID | Detail |
|---|---|---|
| Mucinoses | D017520 | 2 associated lipids |
| Ocular Motility Disorders | D015835 | 2 associated lipids |
| Oliguria | D009846 | 2 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Fibroadenoma | D018226 | 2 associated lipids |
| Pityriasis Lichenoides | D017514 | 2 associated lipids |
| Intracranial Thrombosis | D020767 | 2 associated lipids |
| Labyrinthitis | D007762 | 2 associated lipids |
| Paraproteinemias | D010265 | 2 associated lipids |
| Amputation, Traumatic | D000673 | 2 associated lipids |
| Anemia, Refractory, with Excess of Blasts | D000754 | 2 associated lipids |
| Kidney Tubular Necrosis, Acute | D007683 | 3 associated lipids |
| Scleritis | D015423 | 3 associated lipids |
| Digestive System Diseases | D004066 | 3 associated lipids |
| Pemphigus, Benign Familial | D016506 | 3 associated lipids |
| Ileus | D045823 | 3 associated lipids |
| Anemia, Refractory | D000753 | 3 associated lipids |
| Wounds, Stab | D014951 | 3 associated lipids |
| Uveitis, Intermediate | D015867 | 3 associated lipids |
| Legionellosis | D007876 | 3 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Singh K et al. | Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. | 2014 | Am. J. Transplant. | pmid:25359003 |
| Dugast E et al. | Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. | 2016 | Am. J. Transplant. | pmid:27367750 |
| Tang Q | Pharmacokinetics of therapeutic Tregs. | 2014 | Am. J. Transplant. | pmid:25358900 |
| Sikma MA et al. | Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. | 2015 | Am. J. Transplant. | pmid:26053114 |
| Ellis CL and Racusen LC | Mild rise in creatinine six months post kidney transplant. | 2012 | Am. J. Transplant. | pmid:22845913 |
| Zafrani L et al. | Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. | 2009 | Am. J. Transplant. | pmid:19538494 |
| Touzot M et al. | Renal transplantation in HIV-infected patients: the Paris experience. | 2010 | Am. J. Transplant. | pmid:20840478 |
| Krämer BK et al. | Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. | 2010 | Am. J. Transplant. | pmid:20840480 |
| TruneÄka P et al. | Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. | 2010 | Am. J. Transplant. | pmid:20840481 |
| Wang Q et al. | Biodegradable microsphere-loaded tacrolimus enhanced the effect on mice islet allograft and reduced the adverse effect on insulin secretion. | 2004 | Am. J. Transplant. | pmid:15084166 |
| Schubert M et al. | Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. | 2004 | Am. J. Transplant. | pmid:15084173 |
| ter Meulen CG et al. | Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. | 2004 | Am. J. Transplant. | pmid:15084178 |
| Borrows R et al. | Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. | 2004 | Am. J. Transplant. | pmid:15476485 |
| Hernández-Fisac I et al. | Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. | 2007 | Am. J. Transplant. | pmid:17725683 |
| Budde K et al. | Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. | 2010 | Am. J. Transplant. | pmid:20121745 |
| Artz MA et al. | Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. | 2004 | Am. J. Transplant. | pmid:15147428 |
| Hirsch HH et al. | Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. | 2013 | Am. J. Transplant. | pmid:23137180 |
| Mujtaba MA et al. | Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. | 2014 | Am. J. Transplant. | pmid:25179306 |
| Shihab FS et al. | Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. | 2013 | Am. J. Transplant. | pmid:23167508 |
| Alloway RR et al. | A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. | 2012 | Am. J. Transplant. | pmid:22759200 |
| Hesselink DA et al. | Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. | 2005 | Am. J. Transplant. | pmid:15816878 |
| Byrne GW et al. | Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. | 2005 | Am. J. Transplant. | pmid:15816881 |
| Lucey MR et al. | A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. | 2005 | Am. J. Transplant. | pmid:15816894 |
| Pillebout E et al. | Renal histopathological lesions after orthotopic liver transplantation (OLT). | 2005 | Am. J. Transplant. | pmid:15816895 |
| Muthusamy AS et al. | Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. | 2008 | Am. J. Transplant. | pmid:18828772 |
| Van Laecke S et al. | Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. | 2009 | Am. J. Transplant. | pmid:19624560 |
| Tydén G et al. | ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. | 2005 | Am. J. Transplant. | pmid:15636623 |
| Woodle ES et al. | A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. | 2005 | Am. J. Transplant. | pmid:15636625 |
| Mian AN et al. | Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. | 2005 | Am. J. Transplant. | pmid:15636628 |
| Gregoor PS and Weimar W | Tacrolimus and pure red-cell aplasia. | 2005 | Am. J. Transplant. | pmid:15636632 |
| Gao R et al. | Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells. | 2007 | Am. J. Transplant. | pmid:17391142 |
| Tremblay S et al. | A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. | 2017 | Am. J. Transplant. | pmid:27340950 |
| Momper JD et al. | The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. | 2011 | Am. J. Transplant. | pmid:21714845 |
| Lemahieu WP et al. | CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. | 2004 | Am. J. Transplant. | pmid:15307840 |
| Fan DM et al. | Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. | 2015 | Am. J. Transplant. | pmid:25808777 |
| Servais A et al. | Interstitial fibrosis evolution on early sequential screening renal allograft biopsies using quantitative image analysis. | 2011 | Am. J. Transplant. | pmid:21672152 |
| Mulay AV et al. | Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. | 2009 | Am. J. Transplant. | pmid:19353768 |
| Mazariegos GV et al. | Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. | 2005 | Am. J. Transplant. | pmid:15643991 |
| Bahra M et al. | MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. | 2005 | Am. J. Transplant. | pmid:15644002 |
| Ryan CM and Swanson DP | clinical research, innovative practice and IRB review: identifying and respecting boundaries. | 2007 | Am. J. Transplant. | pmid:17331113 |
| Bunnapradist S et al. | Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. | 2013 | Am. J. Transplant. | pmid:23279614 |
| Ceschi A et al. | Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. | 2013 | Am. J. Transplant. | pmid:23279718 |
| Kaplan B and Kirk AD | Tacrolimus and sirolimus: when bad things happen to good drugs. | 2006 | Am. J. Transplant. | pmid:16827845 |
| McAlister VC et al. | Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. | 2006 | Am. J. Transplant. | pmid:16827858 |
| Vanhove T et al. | High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. | 2016 | Am. J. Transplant. | pmid:27013142 |
| Posselt AM et al. | Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. | 2010 | Am. J. Transplant. | pmid:20659093 |
| Echeverri GJ et al. | Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. | 2009 | Am. J. Transplant. | pmid:19775318 |
| Barbas AS et al. | Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. | 2013 | Am. J. Transplant. | pmid:23331705 |
| Gatault P et al. | Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. | 2017 | Am. J. Transplant. | pmid:27862923 |
| Miller LW | Cardiovascular toxicities of immunosuppressive agents. | 2002 | Am. J. Transplant. | pmid:12392286 |